Reckitt Benckiser Group PLC on Thursday framed emerging markets as a priority in growing its Core business, ahead of an investor seminar.
This segment includes Reckitt’s ‘powerbrands’ - such household names as Dettol, Durex, Finish, Gaviscon, Harpic, Lysol, Mucinex, Nurofen, Strepsils, Vanish and Veet.
Shares in the Slough, England-based firm rose 0.5% to 5,956.00 pence on Thursday morning in London.
The consumer health and hygiene product seller is aiming for high single-digit revenue growth from emerging markets, on a like-for-like basis.
This will support its medium-term target of Core LFL sales growth ranging from 4% to 5%, the firm said. The 2025 target stands between 3% and 4%, with Core LFL sales in 2024 having grown 3.3.%.
In 2024, the Core Reckitt business contributed 71% to net revenue, with emerging market comprising roughly 39% of Core sales.
Reckitt stressed that ‘no new material financial or trading information’ will be shared at its investor seminar on Thursday.
Copyright 2025 Alliance News Ltd. All Rights Reserved.
